Abstract
The recent findings on the roles of death-associated protein 6/α-thalassemia/mental retardation X-linked (DAXX/ATRX) in the development of pancreatic neuroendocrine tumors (PanNETs) have led to major advances in the molecular understanding of these rare tumors and open up completely new therapeutic windows. This overview aims at giving a simplified view on these findings and their possible therapeutic implications. The importance of epigenetic changes in PanNET is also underlined by recent findings of a cross-species study on microRNA (miRNA) and messenger RNA (mRNA) profiles in PanNETs.
Similar content being viewed by others
References
Halfdanarson TR, Rubin J, Farnell MB et al. (2008) Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 15(2):409–427
Jiao Y, Shi C, Edil BH et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199–1203
Marinoni I, Kurrer AS, Vassella E et al. (2014) Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146(2):453–460 e5
Heaphy CM, de Wilde RF, Jiao Y et al. (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333(6041):425
Maze I, Noh KM Allis CD (2013) Histone regulation in the CNS: basic principles of epigenetic plasticity. Neuropsychopharmacology 38(1):3–22
Jonkers YM, Claessen SM, Perren A et al. (2005) Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr Relat Cancer 12(2):435–447
Zhao J, Moch H, Scheidweiler AF et al. (2001) Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 32(4):364–372
Kong CM, Lee XW Wang X (2013) Telomere shortening in human diseases. FEBS J 280(14):3180–3193
Anlauf M, Enosawa T, Henopp T et al. (2008) Primary lymph node gastrinoma or occult duodenal microgastrinoma with lymph node metastases in a MEN1 patient: the need for a systematic search for the primary tumor. Am J Surg Pathol 32(7):1101–1105
de Wilde RF, Heaphy CM, Maitra A et al. (2012) Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol 25(7):1033–1039
Puto LA Reed JC (2008) Daxx represses RelB target promoters via DNA methyltransferase recruitment and DNA hypermethylation. Genes Dev 22(8):998–1010
Meissner A, Mikkelsen TS, Gu H et al. (2008) Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454(7205):766–770
Pipinikas CP, Dibra H, Karpathakis A et al. (2015) Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer 22(3):L13–L18
Stefanoli M, La Rosa S, Sahnane N et al. (2014) Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors. Neuroendocrinology 100(1):26–34
Flynn RL, Cox KE, Jeitany Met al. (2015) Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347(6219):273–277
Juo YY, Gong XJ, Mishra A et al. (2015) Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics 7(2):215–235
Zahnow CA, Topper M, Stone M et al. (2016) Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy. Adv Cancer Res 130:55–111
Sadanandam A, Wullschleger S, Lyssiotis CA et al. (2015) A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discov 5(12):1296–1313
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmitt, A.M., Marinoni, I., Blank, A. et al. New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies. Endocr Pathol 27, 200–204 (2016). https://doi.org/10.1007/s12022-016-9447-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12022-016-9447-2